Duchenne muscular dystrophy (DMD) is an intractable X-linked myopathy caused by dystrophin gene mutations. Patients with DMD suffer from progressive muscle weakness, inevitable cardiomyopathy, increased heart rate (HR), and decreased blood pressure (BP). The aim of this study was to clarify the efficacy and tolerability of ivabradine treatment for DMD cardiomyopathy.A retrospective analysis was performed in 11 patients with DMD, who received ivabradine treatment for more than 1 year. Clinical results were analyzed before (baseline), 6 months after, and 12 months after the ivabradine administration.The initial ivabradine dose was 2.0 ± 1.2 mg/day and the final dose was 5.6 ± 4.0 mg/day. The baseline BP was 95/64 mmHg. A non-significant BP decrease to 90/57 mmHg was observed at 1 month but it recovered to 97/62 mmHg at 12 months after ivabradine administration. The baseline HR was 93 ± 6 bpm and it decreased to 74 ± 12 bpm at 6 months (P = 0.011), and to 77 ± 10 bpm at 12 months (P = 0.008). A linear correlation (y = 2.2x + 5.1) was also observed between the ivabradine dose (x mg/day) and HR decrease (y bpm). The baseline LVEF was 38 ± 12% and it significantly increased to 42 ± 9% at 6 months (P = 0.011) and to 41 ± 11% at 12 months (P = 0.038). Only 1 patient with the lowest BMI of 11.0 kg/m and BP of 79/58 mmHg discontinued ivabradine treatment at 6 months, while 1-year administration was well-tolerated in the other 10 patients.Ivabradine decreased HR and increased LVEF without lowering BP, suggesting it can be a treatment option for DMD cardiomyopathy.

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.23-563DOI Listing

Publication Analysis

Top Keywords

ivabradine treatment
12
dose mg/day
12
efficacy tolerability
8
ivabradine
8
tolerability ivabradine
8
duchenne muscular
8
muscular dystrophy
8
patients dmd
8
months
8
months ivabradine
8

Similar Publications

Evaluation of Prescription Pattern of Antihypertensives and Its Compliance with Joint National Committee 8 Guidelines in Hospital Setting.

J Assoc Physicians India

December 2024

Senior Consultant, Interventional Cardiologist, and Electrophysiologist, Department of Cardiology, Aditya Birla Memorial Hospital, Pune, Maharashtra, India.

Globally, hypertension is a major noncommunicable disease that contributes to significant fatalities and morbidity. Evaluation of trends in the prescription of antihypertensives and their adherence to the Joint National Commission 8 (JNC 8) recommendations can provide perspective on the dissemination of local and international guidelines in real-world clinical practice. An ambispective observational study was conducted over a duration of 6 months.

View Article and Find Full Text PDF

Introduction: Although amiodarone is traditionally used in the treatment of postoperative junctional ectopic tachycardia (JET), the search for new treatments is ongoing. We present our experience with ivabradine at two medical centers.

Materials And Methods: Between January 2022 and January 2023, patients who developed JET after pediatric cardiac surgery were prospectively followed up and documented.

View Article and Find Full Text PDF

Purpose: For Long COVID autonomic dysfunction, we have summarized published evidence on treatment effectiveness, clinical practice guidelines, and unpublished/ongoing studies.

Methods: We first interviewed 11 stakeholders (clinicians, clinician/researchers, payors, patient advocates) to gain clinical insights and identify key areas of focus. We searched Embase, CINAHL, Medline, PsycINFO, and PubMed databases for relevant English-language articles published between 1 January 2020 and 30 April 2024.

View Article and Find Full Text PDF

Background: Ivabradine has been identified as a funny current (If) inhibitor in the sinoatrial node (SAN) and is considered an advocated therapeutic agent in chronic heart failure and stable angina. This therapeutic agent has shown positive benefits in maintaining a reduction in heart rate while sustaining hemodynamic stability. Its clinical application is still evolving and the mechanism of action is becoming clearer daily.

View Article and Find Full Text PDF
Article Synopsis
  • Ivabradine is a new treatment for heart rate reduction in patients with reduced ejection fraction heart failure, and this study evaluates its cost-effectiveness in Japan.
  • A Markov model was used to compare ivabradine plus standard therapy against standard therapy alone, focusing on Quality-Adjusted Life Years (QALY) for patients with resting heart rates ≥ 75 bpm and ≥ 70 bpm.
  • The study found that ivabradine is likely cost-effective, with an incremental cost-effectiveness ratio of around JPY 2.46 million to JPY 2.56 million per QALY, making it a viable option for patients with chronic heart failure in Japan.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!